Investor Relations

Overview

Nabriva Therapeutics is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a current focus on the pleuromutilin class of antibiotics. Our lead product candidate, lefamulin, is being developed as the first pleuromutilin antibiotic for intravenous (IV) and oral administration in humans. We reported positive top-line efficacy and favorable tolerability data from the LEAP 1 Phase 3 trial in September 2017 for community-acquired bacterial pneumonia (CABP). Additionally, we anticipate receiving top-line results for LEAP 2 in CABP during the spring of 2018. We also plan to develop lefamulin for additional uses and are working to build a robust pipeline of anti-infective products. Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.

Events & Presentations

Upcoming
More events are coming soon.

SEC Filings

Filing date Description Form Filing Group View

Registration statement for certain foreign private issuers

F-1
Registration Statements
View HTML

This filing is a pre-effective amendment to an F-1 filing

F-1/A
Registration Statements
View HTML

This filing is a pre-effective amendment to an F-1 filing

F-1/A
Registration Statements
View HTML

Investor Contacts

David Garrett
Vice President, Corporate Controller and Head of Investor Relations Nabriva Therapeutics plc
E-mail: david.garrett@nabriva.com